Patent Evaluation Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Matrix metalloproteinase inhibitors

Abstract

This patent from DuPont Merck discloses three distinct series of matrix metalloproteinase (MMP) inhibitors based on the N-carboxyalkyl, carboxylic acid and hydroxamic acid zinc binding groups, respectively. The common feature of these compounds is the presence of a carbocyclic or heterocyclic ring (typically the piperazic acid residue found in the matlystatins) in place of a conventional P2′ amino acid residue. Representative compounds from each series are shown to inhibit stromelysin and oral bioavailability is demonstrated for certain of the hydroxamic acids. The compounds of the invention are said to be useful in the treatment of diseases involving connective tissue breakdown, particularly osteo and rheumatoid arthritis.